However, published data demonstrate that a reduction in Serca2 expression reduces cardiac contractility and accelerates the progression to heart failure [52], in contrast to the hypercontractile phenotype and lack of systolic dysfunction seen in caFGFR1-induced HCM. Here, ATP2A2 is linked to heart failure.